What is claimed is:

1. A solid form comprising Compound 1:



1.

2. The solid form of claim 1, comprising a free base of Compound 1.

3. The solid form of claim 2, which is Form A of a free base of Compound 1, characterized by an XRPD pattern comprising peaks at approximately 4.5, 15.3, and 18.1º 2θ.

4. The solid form of claim 3, wherein the XRPD pattern further comprises peaks at approximately 13.3 and 15.9º 2θ.

5. The solid form of claim 4, wherein the XRPD pattern further comprises peaks at approximately 20.1 and 20.9º 2θ.

6. The solid form of claim 3, which is characterized by an XRPD pattern that matches the XRPD pattern presented in **FIG. 1**.

7. The solid form of claim 2, which is Form B of a free base of Compound 1, characterized by an XRPD pattern comprising peaks at approximately 4.8, 9.6, and 14.9º 2θ.

8. The solid form of claim 7, wherein the XRPD pattern further comprises peaks at approximately 18.7 and 22.1º 2θ.

9. The solid form of claim 8, wherein the XRPD pattern further comprises peaks at approximately 20.7 and 21.4º 2θ.

10. The solid form of claim 7, which is characterized by an XRPD pattern that matches the XRPD pattern presented in **FIG. 3**.

11. The solid form of claim 1, comprising a hydrochloride salt of Compound 1.

12. The solid form of claim 11, which is Form A of a hydrochloride salt of Compound 1, characterized by an XRPD pattern comprising peaks at approximately 15.1, 16.3, and 20.7º 2θ.

13. The solid form of claim 12, wherein the XRPD pattern further comprises peaks at approximately 7.8 and 22.4º 2θ.

14. The solid form of claim 13, wherein the XRPD pattern further comprises peaks at approximately 18.2, 18.9, and 24.8º 2θ.

15. The solid form of claim 12, which is characterized by an XRPD pattern that matches the XRPD pattern presented in **FIG. 5**.

16. The solid form of claim 11, which is Form B of a hydrochloride salt of Compound 1, characterized by an XRPD pattern comprising peaks at approximately 17.5, 21.6, and 24.8º 2θ.

17. The solid form of claim 16, wherein the XRPD pattern further comprises peaks at approximately 21.1 and 27.0º 2θ.

18. The solid form of claim 17, wherein the XRPD pattern further comprises peaks at approximately 14.6, 17.2, and 20.3º 2θ.

19. The solid form of claim 16, which is characterized by an XRPD pattern that matches the XRPD pattern presented in **FIG. 9**.

20. The solid form of claim 1, comprising a fumarate salt of Compound 1.

21. The solid form of claim 20, which is Form A of a fumarate salt of Compound 1, characterized by an XRPD pattern comprising peaks at approximately 22.3, 23.2, and 23.4º 2θ.

22. The solid form of claim 21, wherein the XRPD pattern further comprises peaks at approximately 17.9 and 25.8º 2θ.

23. The solid form of claim 22, wherein the XRPD pattern further comprises peaks at approximately 11.7 and 18.3º 2θ.

24. The solid form of claim 21, which is characterized by an XRPD pattern that matches the XRPD pattern presented in **FIG. 11**.

25. The solid form of claim 1, comprising a tosylate salt of Compound 1.

26. The solid form of claim 25, which is Form A of a tosylate salt of Compound 1, characterized by an XRPD pattern comprising peaks at approximately 17.6, 18.0, and 23.8º 2θ.

27. The solid form of claim 26, wherein the XRPD pattern further comprises peaks at approximately 15.7 and 20.6º 2θ.

28. The solid form of claim 27, wherein the XRPD pattern further comprises peaks at approximately 24.7 and 25.0º 2θ.

29. The solid form of claim 26, which is characterized by an XRPD pattern that matches the XRPD pattern presented in **FIG. 13**.

30. The solid form of claim 1, comprising a maleate salt of Compound 1.

31. The solid form of claim 30, which is Form A of a maleate salt of Compound 1, characterized by an XRPD pattern comprising peaks at approximately 17.6, 24.4, and 26.9º 2θ.

32. The solid form of claim 31, wherein the XRPD pattern further comprises peaks at approximately 18.0, 18.4, and 19.3º 2θ.

33. The solid form of claim 32, wherein the XRPD pattern further comprises peaks at approximately 19.8 and 24.0º 2θ.

34. The solid form of claim 31, which is characterized by an XRPD pattern that matches the XRPD pattern presented in **FIG. 15**.

35. The solid form of claim 1, comprising a besylate salt of Compound 1.

36. The solid form of claim 35, which is Form A of a besylate salt of Compound 1, characterized by an XRPD pattern comprising peaks at approximately 17.9, 18.3, and 23.8º 2θ.

37. The solid form of claim 36, wherein the XRPD pattern further comprises peaks at approximately 15.7 and 16.2º 2θ.

38. The solid form of claim 37, wherein the XRPD pattern further comprises peaks at approximately 8.5 and 16.5º 2θ.

39. The solid form of claim 36, which is characterized by an XRPD pattern that matches the XRPD pattern presented in **FIG. 17**.

40. A salt of Compound 1:



1.

41. The salt of claim 40, which is a hydrochloride salt, a fumarate salt, a tosylate salt, a maleate salt, or a besylate salt.

42. The salt of claim 40 or 41, which is a crystalline salt.

43. A pharmaceutical composition comprising a solid form of any one of claims 1 to 39 or a salt of any one of claims 40 to 42, and a pharmaceutically acceptable excipient or carrier.

44. Use of a solid form of any one of claims 1 to 39 or a salt of any one of claims 40 to 42 in the manufacture of a medicament for treating a hematological malignancy, wherein a therapeutically effective amount of the solid form or the salt is to be administered to a patient in need thereof.

45. The use of claim 44, wherein the hematological malignancy is acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), multiple myeloma (MM), non-Hodgkin's lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), Hodgkin's lymphoma (HL), T-cell lymphoma (TCL), Burkitt lymphoma (BL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), marginal zone lymphoma (MZL), or myelodysplastic syndromes (MDS).

46. A solid form of any one of claims 1 to 39 or a salt of any one of claims 40 to 42 for use in treating a hematological malignancy, wherein a therapeutically effective amount of the solid form or the salt is to be administered to a patient in need thereof.

47. The solid form or salt for use of claim 46, wherein the hematological malignancy is acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), multiple myeloma (MM), non-Hodgkin's lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), Hodgkin's lymphoma (HL), T-cell lymphoma (TCL), Burkitt lymphoma (BL), chronic lymphocytic leukemia/small

lymphocytic lymphoma (CLL/SLL), marginal zone lymphoma (MZL), or myelodysplastic syndromes (MDS).

48. A solid form of any one of claims 1 to 39 or a salt of any one of claims 40 to 42 for use in therapy.